{"product_id":"inotivco-five-forces-analysis","title":"Inotiv Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eInotiv operates within a niche life-sciences testing market where supplier specialization and regulatory pressures shape competitive dynamics, while buyer concentration and potential CRO substitutes influence pricing and margin resilience.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Inotiv’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Research Model Supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvailability of patented and limited-vendor genetically modified models gives suppliers high leverage over Inotiv’s nonclinical services pricing and lead times; industry reports show 60–70% of specialized strains come from ≤3 suppliers as of 2025. Inotiv reduced this risk by acquiring research-model businesses (including XenoTech acquisition 2023), integrating vertically to capture ~25% of its model needs internally and stabilize delivery and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Scientific Personnel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpthe market for experienced toxicologists pathologists and regulatory experts stayed tight through with us median toxicologist salaries rising to in specialist recruiter margins of driving higher hiring costs cros like inotiv.\u003e\n\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory Equipment and Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInotiv depends on a concentrated set of global suppliers for advanced analytical instruments and specialty reagents, giving suppliers strong leverage; top vendors like Agilent and Thermo Fisher control ~40–60% of high-end lab instrument market share as of 2024. Maintenance contracts and strict technical specs raise switching costs and recurring spend—Inotiv likely allocates \u0026gt;10% of COGS to equipment servicing. Any supply disruption can delay studies: a 2–6 week instrument lead time often shifts project timelines and raises operational inefficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Facility and Utility Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialized facility and utility providers hold strong leverage over Inotiv because its animal housing and labs use large-scale HVAC and power systems; U.S. lab energy intensity averages ~3,000 kWh\/m2\/year, so a 10% price rise meaningfully raises operating margins.\u003c\/p\u003e\n\u003cp\u003eLocal suppliers are hard to replace—relocating facilities costs hundreds of millions—so shifts in energy regulations or infrastructure tariffs directly increase overhead and cash burn.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLab energy ≈3,000 kWh\/m2\/yr\u003c\/li\u003e\n\u003cli\u003e10% energy price rise → notable margin pressure\u003c\/li\u003e\n\u003cli\u003eRelocation cost: likely hundreds of millions\u003c\/li\u003e\n\u003cli\u003eRegulatory tariff changes immediately affect OPEX\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe transport of biological samples and live research models needs specialized cold-chain carriers that keep strict temperature and animal welfare standards, and only a few global firms (DHL Life Sciences, World Courier, Marken) have that cross-border capacity, concentrating supplier power.\u003c\/p\u003e\n\u003cp\u003eThose carriers can impose surcharges; in 2024 air-freight rates rose ~18% year-over-year and pharma cold-chain premiums averaged 12–20%, letting logistics providers pass fuel, regulatory, and handling costs to Inotiv.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew global specialists: DHL, World Courier, Marken\u003c\/li\u003e\n\u003cli\u003e2024 air-freight +18% YoY\u003c\/li\u003e\n\u003cli\u003eCold-chain premiums 12–20%\u003c\/li\u003e\n\u003cli\u003eHigh switching cost; regulatory paperwork cross-borders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier squeeze raises costs: concentrated inputs, premium logistics, rising labor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power: 60–70% of specialized strains come from ≤3 vendors (2025), top instrument makers (Agilent, Thermo Fisher) control ~40–60% (2024), and DHL\/World Courier\/Marken dominate cold‑chain; Inotiv internalized ~25% of models after XenoTech (2023) to cut risk. Key costs: toxicologist pay +12% to ~$145k (2024), air freight +18% (2024), cold‑chain premiums 12–20%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialized strain concentration (2025)\u003c\/td\u003e\n\u003ctd\u003e60–70% ≤3 suppliers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstrument market share (2024)\u003c\/td\u003e\n\u003ctd\u003e40–60% top vendors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInotiv vertical supply coverage\u003c\/td\u003e\n\u003ctd\u003e~25% post‑2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eToxicologist median pay (2024)\u003c\/td\u003e\n\u003ctd\u003e~$145,000 (+12%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAir freight change (2024)\u003c\/td\u003e\n\u003ctd\u003e+18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain premium\u003c\/td\u003e\n\u003ctd\u003e12–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Inotiv that uncovers competitive drivers, supplier and buyer power, entry barriers, substitutes, and disruptive threats—supported by industry data and strategic commentary for use in investor materials, strategy decks, or academic projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, one-sheet Porter's Five Forces view for Inotiv—instantly shows competitive pressure, customizable inputs for evolving biotech market shifts, and a ready-to-use radar chart to drop into decks or reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Large Pharmaceutical Clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplarge pharma clients account for roughly of revenue many cros letting them press inotiv lower rates during negotiations reported so a few big accounts can swing margins materially. these firms run internal audits and demand audit-ready data transparency raising compliance costs. their ability to shift multi-year contracts renewal churn annually strong leverage at renewal.\u003e\n\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech Funding and Spending Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSmall- and mid-sized biotech firms, which make up roughly 45% of Inotiv’s client base, are highly sensitive to capital markets; VC biotech funding fell 28% in 2023 and global biotech IPOs dropped 62% that year, so program delays are common.\u003c\/p\u003e\n\u003cp\u003eWhen VC rounds tighten or rates rise, startups often pause discovery work to conserve cash, creating buyer leverage that forces Inotiv to offer flexible payment terms, phased milestones, or bundled preclinical packages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Active Studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOnce an Inotiv preclinical study starts, switching CROs is costly and regulatory-heavy, cutting buyer power mid-project; data continuity and IND\/NDA filings tie to lab protocols, raising effective exit costs often \u0026gt;$200k per study and months of delay.\u003c\/p\u003e\n\u003cp\u003eThat leverage applies only post-contract, so initial bids remain competitive; in 2024 the outsourced preclinical market grew 6.8% to $12.4B, intensifying bid pressure for new work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Integrated Service Portfolios\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern drug developers prefer one-stop-shop providers for discovery through IND-enabling work, so customers can consolidate spend and favor full-service CROs; as of 2024, 64% of biopharma firms reported preferring integrated vendors for complex programs, boosting buyer leverage.\u003c\/p\u003e\n\u003cp\u003eThis gives customers power to threaten moving spend to larger CROs if Inotiv lacks breadth, forcing Inotiv to expand capabilities—Inotiv’s 2024 R\u0026amp;D service revenue mix showed pressure to grow integrated offerings to protect contracts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e64% of firms prefer integrated vendors (2024 survey)\u003c\/li\u003e\n\u003cli\u003eConsolidation risk raises contract loss probability\u003c\/li\u003e\n\u003cli\u003eInotiv must expand services to retain large program spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRigorous Quality and Compliance Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClients force Inotiv to meet evolving FDA, EMA and ICH standards and bespoke buyer QA specs, with failure risking remediation, contract loss, or price cuts—site audits rose 22% industry-wide in 2024 per IQVIA.\u003c\/p\u003e\n\u003cp\u003eIntensive inspections let buyers demand corrective actions or rebates; 40% of preclinical contracts in 2023 included performance-linked penalties, so Inotiv must comply to stay a qualified supplier.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuyers mandate global regs (FDA\/EMA\/ICH) and internal QA\u003c\/li\u003e\n\u003cli\u003eSite audits up 22% in 2024 (IQVIA)\u003c\/li\u003e\n\u003cli\u003e40% contracts had performance penalties in 2023\u003c\/li\u003e\n\u003cli\u003eNoncompliance risks remediation, price cuts, lost contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClients wield pricing power as startups cut programs—Inotiv $201.6M amid $12.4B market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpcustomers hold high bargaining power: top pharma clients of cro revenue can force price cuts inotiv was startups client mix cut programs when funding falls biotech dropped in demand for flexible terms. switching mid-study is costly\u003e $200k, months), reducing power post-contract, but market growth (outsourced preclinical $12.4B in 2024) keeps bid pressure.\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInotiv 2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$201.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-client revenue share\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClient startups share\u003c\/td\u003e\n\u003ctd\u003e≈45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutsourced preclinical market 2024\u003c\/td\u003e\n\u003ctd\u003e$12.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVC biotech funding change 2023\u003c\/td\u003e\n\u003ctd\u003e−28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pcustomers\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eInotiv Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Inotiv Porter's Five Forces Analysis you'll receive immediately after purchase—no placeholders, no mockups. The document displayed is the complete, professionally formatted file, ready for download and use the moment you buy. You're viewing the final deliverable, containing the full competitive-force assessment and actionable insights. What you see is precisely what you'll get upon payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746980770169,"sku":"inotivco-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/inotivco-five-forces-analysis.png?v=1772193839","url":"https:\/\/matrixbcg.com\/products\/inotivco-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}